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Abstract
Cancer cells upregulate anabolic processes to maintain high rates of cellular turnover. Limiting the supply of
macromolecular precursors by targeting enzymes involved in biosynthesis is a promising strategy in cancer therapy.
Several tumors excessively metabolize glutamine to generate precursors for nonessential amino acids, nucleotides,
and lipids, in a process called glutaminolysis. Here we show that pharmacological inhibition of glutaminase (GLS)
eradicates glioblastoma stem-like cells (GSCs), a small cell subpopulation in glioblastoma (GBM) responsible for therapy
resistance and tumor recurrence. Treatment with small molecule inhibitors compound 968 and CB839 effectively
diminished cell growth and in vitro clonogenicity of GSC neurosphere cultures. However, our pharmaco-metabolic
studies revealed that only CB839 inhibited GLS enzymatic activity thereby limiting the influx of glutamine derivates
into the TCA cycle. Nevertheless, the effects of both inhibitors were highly GLS specific, since treatment sensitivity
markedly correlated with GLS protein expression. Strikingly, we found GLS overexpressed in in vitro GSC models as
compared with neural stem cells (NSC). Moreover, our study demonstrates the usefulness of in vitro pharmaco-
metabolomics to score target specificity of compounds thereby refining drug development and risk assessment.
Introduction
Metabolic reprogramming of bioenergetic and biosyn-
thetic processes is a key event in malignant transforma-
tion1. Tumor cells can maintain high proliferation rates by
enhanced uptake and metabolism of glucose and gluta-
mine (Gln) thereby fueling the two main anaplerotic
pathways providing tricarboxylic acid (TCA) cycle
intermediates to boost oxidative phosphorylation and
biomass production2. Since glycolysis and glutaminolysis
are dysregulated in neoplastic cells and tissues due to
epigenetic and mutational changes3–6, they are compel-
ling therapeutic targets in cancer therapy. However, the
clinical application of glycolysis inhibitors remains chal-
lenging mainly due to adverse effects7,8. Alternative stra-
tegies of metabolic interference in cancer therapy have
recently emerged including the restriction of glutamino-
lytic activity. Mitochondrial glutaminase (GLS) catalyzes
the hydrolytic deamidation of Gln to glutamate (Glu) in
the first step of glutaminolysis. Subsequently, Glu is either
metabolized to the TCA cycle intermediate alpha-
ketoglutarate (αKG), which is then used as a nitrogen-
donor during the synthesis of several nonessential amino
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acids, or mediates redox homeostasis by increasing the
production of the antioxidant glutathione (GSH). Since
several oncogenes regulate GLS expression and many
studies have shown that cancer cells are GLS-
dependent3,9,10, GLS inhibitors (GLSi) (have been
designed and evaluated in preclinical and clinical trials for
brain tumors (trial ID: NCI-2018-00876)11–13. The spe-
cific and orally bioavailable small molecule inhibitor
CB839 has been shown to effectively reduce viability,
chemosensitivity, and induce apoptosis in several tumor
entities including breast, ovarian, prostate, and lung
cancer14–17. Furthermore, compound 968 (C968), another
small molecule GLS inhibitor, has been reported to impair
tumor cell clonogenicity, viability, and growth18–23.
Glioblastoma (GBM), the most aggressive malignant brain
tumor, expresses high levels of GLS however their
dependency on Gln metabolism remains controversial24.
Several studies report that GBMs depend on glutamino-
lysis to sustain cellular viability and TCA cycle ana-
plerosis4,25,26. However, others report that growth
inhibition upon Gln withdrawal is cell line-specific and
that resistant cell lines upregulate alternative metabolic
routes to compensate for the lack of nutrient supply27.
Here we analyze the effect of GLS inhibition on stem cell-
enriched GBM in vitro models (GBM stem-like cells;
GSCs), which have been suggested to be responsible for
the emergence of therapy resistance and tumor relapse28–31.
Accumulating evidences indicate that GSCs are
characterized by distinct metabolic reprogramming and
interfering in this may be a suitable strategy to combat
those highly therapy resistance population of cells32–34.
We assessed the therapeutic potential of two prominent
GLSi on GSCs in vitro and validated GLS as a target with
low adverse effects. Furthermore, the pharmaco-
metabolic characterization of our in vitro models upon
compound exposure highlights the potential of this
technology for the risk assessment of drug candidates.
Results
GSC in vitro models recapitulate the glutaminase
expression status of patient samples
In order to assess the relevance of GLS in human GBM
tumors, tumor bulk samples of seven primary GBMs were
homogenized and subjected to immunoblotting for GLS
protein. GLS was clearly expressed in all GBMs although
expression varied markedly between tumors (Fig. 1a).
That suggests, that the susceptibility of a patients GBM to
GLS inhibition varies as well. Publicly available mRNA
expression data showed that GLS is markedly over-
expressed in the leading edge of the tumor and infiltrating
tumor tissue (Fig. 1b) and it is thought that these tumor
compartments promote GSC enrichment through a
mechanism called epithelial–mesenchymal (EMT)-like
transition35. Concisely, GLS has been reported to regulate
the expression of EMT markers in colorectal cancer36,37.
To assess GLS expression in stem cell-enriched GBM
Fig. 1 Primary GBM samples (in vivo) and stem-cell enriched GSC cultures (in vitro) show the same variation in GLS protein expression. a
GLS protein expression was assessed in seven primary glioblastoma (pGBM) samples and compared with the loading control (β actin). b RNA
sequencing data from the IVY glioblastoma project showing differential GLS expression in five tumor structures (Leading Edge, Infiltrating Tumor,
Cellular Tumor, Microvascular Proliferation, and Pseudopalisading Cells around Necrosis), the hyperplastic blood vessels, and the microvascular
proliferative region from 10 different tumors. *significantly decreased (p < 0.05) compared with Leading Edge. #significantly decreased (p < 0.05)
compared with Infiltrating Tumor. Statistical significance was tested with a one-way ANOVA plus Bonferroni’s multiple comparisons test. The data are
represented as mean ± SD (n= 19–122, see “Methods” section for details). c GLS protein expression in NSCs and nine GSC cultures was assessed with
immunoblotting and compared with the loading control (α tubulin). GLS glutaminase, n.a. not available, NSCs neural stem cells, pGBM primary
glioblastoma.
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cultures, we performed immunoblotting for GLS protein
in nine GSC cultures and compared the expression level
to non-tumorigenic neural stem cells (NSCs) (Fig. 1c).
Strikingly, we observed lowest GLS expression in NSCs
and identified significant variations between the nine GSC
cultures. Hence, we decided to study GLS suppression in
six different GSC neurosphere cultures, three GLS-low
(233, 407, 268) and three GLS-high (GBM1, JHH520,
SF188) expressing ones. Importantly, our selected in vitro
GSC models represent the physiological variation of GLS
expression observed in tumor tissue therefore showing
pathophysiological relevance (Fig. 1a). Verified by pixel
densitometry analysis, the variation in GLS protein
observed in the different primary tumors is similar to the
variation in GLS expression observed between the dif-
ferent GSC in vitro models. For both protein analyses
(Fig. 1a, c), the same experiment conditions were used and
equal amounts of total protein were loaded.
Susceptibility to pharamcological glutaminase inhibition
correlates with elevated GLS expression
To assess the effect of GLS inhibition on tumorigenic
GSCs and estimate possible side effects on non-
tumorigenic stem cells, we treated highly clonogenic
neurosphere cultures derived from human fetal cortical
tissue (neural SC; NSC) with the small molecule GLSi
C968 and CB839 and compared them to GLS-high
(SF188, JHH520 and GBM1) and GLS-low (233, 407,
and 268) expressing GSCs. Fetal NSCs are a commonly
used surrogate for non-tumorigenic stem cells in brain
tumor research38–41. Cell growth of GSC neurospheres
and NSCs treated with increasing concentrations of C968
(Fig. 2a, b), CB839 (Fig. 2c, d), or vehicle (DMSO) was
assessed after two and four days of incubation. In SF188,
JHH520 and GBM1 cells, treatment with both C968 and
CB839 induced a dose-dependent suppression of cell
growth. On the contrary, 233, 407, and 268 showed no
effects to GLS inhibition except for a moderate response
in 407 to C968 and 268 to CB839 exposure. Non-
tumorigenic NSCs were resistant to both C968 and CB839
treatment.
2.3. Glutaminase inhibition selectively impairs the
stemness phenotype of GLS-high expressing cultures
Since GSCs maintain their self-renewal ability they are
capable of growing colonies out of single cells. Therefore,
we tested the in vitro clonogenicity of GSCs upon treat-
ment with 10 µM C968 (Fig. 3a), 1 µM CB839 (Fig. 3b), or
vehicle and compared them to non-tumorigenic NSCs.
Consistent with the results from the growth assays, SF188,
JHH520, and GBM1 cells showed markedly diminished
clonogenic capacity, while the in vitro clonogenicity of
GLS-low expressing cells (233, 407, and 268) was not
affected except for a moderate reduction in 407 cells
treated with C968. We can therefore directly correlate
resistance to GLS inhibition with low protein expression
levels (Fig. 1c). Consistent with our results, both phar-
macological and genetic suppression of GLS protein
caused impaired clonogenic capacity in different tumor
entities17,23,42,43. Although reaching statistical sig-
nificance, the in vitro clonogenicity was barely reduced in
NSCs treated with 1 µM CB839 and moderately reduced
by 10 µM C968 treatment (Fig. 3a, b). The observed
effects were much less severe than observations in pre-
vious studies testing Gln analogs or genetic GLS sup-
pression in non-tumorigenic NSCs44,45. To our
knowledge, our study is the first risk assessment of tar-
geted pharmacological GLS inhibition in NSCs. Again, the
superiority of CB839 as a GLSi becomes obvious, showing
less side effects in NSCs. Previous research directly cor-
related the clonogenic capacity of GSCs with the
expression of GSC stemness marker prominin (CD133)
and EMT activator ZEB131,35,46–48. Immunoblotting ana-
lyses should show whether the impaired clonogenicity we
observed in treated GLS-high expressing GSCs (SF188,
JHH520, GBM1) coincides with reduced CD133 or ZEB1
expression. Both C968 (Fig. 3c) and CB839 (Fig. 3d)
treatment mildly reduced ZEB1 expression both in sen-
sitive (GLS-high) and insensitive (GLS-low) GSCs. Fur-
thermore, CD133 expression was dramatically reduced by
C968 and moderately reduced by CB839 treatment
independent of GLSi sensitivity. Since we observed similar
effects in both sensitive and insensitive GSCs, our results
clearly show that the degree of stemness in GBMs cannot
be exclusively estimated by the expression levels of single
markers like CD133 or ZEB1, but should rather be defined
by phenotypical readouts like the in vitro clonogenicity.
Glutaminase inhibition causes cell cycle arrest in sensitive
GLS-high expressing GSCs
Since functional glutaminolysis is a prerequisite for a
variety of cellular processes, we assessed apoptosis
induction, reactive oxygen species (ROS) accumulation,
GSH concentrations and GSH/GSSG ratios, and the cell
cycle state in GSCs treated with 10 µM C968 or 1 µM
CB839. For those mechanistic studies we chose two GLS-
high (JHH520 and GBM1) and two GLS-low (407 and
233) expressing GSC cultures. In GLS-high expressing
cells, treatment with both inhibitors significantly
increased the percentage of cells in quiescent G0/G1
phase and reduced the percentage of cells in the pro-
liferative S and M/G2 phases (Fig. 4a). However, treat-
ment with C938 and CB839 did not significantly alter the
cell cycle of GLS-low expressing 233 or 407 cells. Fur-
thermore, we calculated the proliferation index as a
measure of cells in proliferative cell cycle phases (PI= (S
+G2/M) / (G0/G1+ S+G2/M) x 100%). We observed a
significant decrease of the PI in JHH520 (−28%), GBM1
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(−11%), and 407 (−11%) upon C968 treatment and in
JHH520 (−24%) and GBM1 (−18%) cells upon CB839
treatment. In lowest GLS expressing 233 cells neither
C968 nor CB839 affected the PI. Furthermore, we co-
stained GSCs treated with GLSi for apoptotic cells with
AnnexinV and 7-AAD. FACS measurements revealed no
significant increase in the percentages of early apoptotic
(EA, AnnexinVpos, 7-AADneg) or late apoptotic (LA,
AnnexinVpos, 7-AADpos) cells upon C968 or CB839
treatment (Fig. 4b). However, when we normalized the
percentages of total apoptotic cells (EA+ LA) in the
treatment conditions to the respective solvent controls we
Fig. 2 Sensitivity to GLS inhibition correlates with high GLS protein expression. Both GLS-high GSCs (SF188, JHH520, GBM1), GLS-low GSCs
(233, 407, 268), and NSCs were exposed to increasing concentrations of GLS inhibitors C968 (a) and CB839 (c). The growth of GSCs and NSCs upon
10 µM C968 (b) and 1 µM CB839 (d) treatment for 48 h was compared with the growth under the respective solvent controls (DMSO). The growth
under solvent control was set to 100%. *, significant compared with the solvent control. ns, not significant compared with the solvent control. #,
significant compared with the inhibitor-effect in NSCs. Cell lines were sorted from highest to lowest GLS protein expression level (n= 3–4, specified
in methods). Statistical significance was calculated with unpaired t-tests. All data are depicted as mean ± SD (*p < 0.05). d days, DMSO
dimethylsulfoxid, n.s. not significant, NSC neural stem cells.
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observed a significant increase in total apoptotic cells by
1.99-fold in JHH520, 1.28-fold in GBM1, and 1.23-fold in
407 cells treated with C968, but saw no effect in 233 cells
(Fig. 4c). CB839 treatment did not significantly induce
apoptosis in any of the cell lines. Since the GLS product
Glu is crucial for the synthesis of the antioxidant GSH, we
Fig. 3 Treatment with C968 and CB839 eradicates tumor initiating cells in GLS-high expressing cultures. GSC cultures and NSCs were treated
with 10 µM C968 (a), 1 µM CB839 (b), or solvent control (DMSO). The number of colonies counted in cells treated with the solvent control (DMSO)
was set to 100%. Displayed are the number of colonies (CFU) in the inhibitor-treated conditions compared with the colonies in the respective solvent
controls (% of solvent control). *, significant compared with the solvent control. ns, not significant compared with the solvent control. #, significant
compared with the inhibitor-effect in NSCs. Representative pictures of NBT stained colonies and quantifications of three soft agar colony formation
assays are shown (n= 3–6, specified in methods). Statistical significance was calculated with unpaired t-tests. Immunoblotting of stemness markers
ZEB1 and CD133 in GSC cultures treated for 48 h with 10 µM C968 (c), 1 µM CB839 (d) or vehicle (DMSO). GSC cultures were sorted according to their
GLS expression level from highest (SF188) to lowest (233) expression (loading control = β actin). All data are depicted as mean ± SD (*p < 0.05). d
days, DMSO dimethylsulfoxid, n.a. not available, NBT nitro blue tetrazolium chloride, n.s. not significant, NSC neural stem cells.
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Fig. 4 (See legend on next page.)
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assessed whether GLS inhibition alters the concentrations
of reduced (GSH) or oxidized (GSSG) glutathione or
affects the GSH/GSSG ratio. Decreased GSH/GSSG ratios
are a measure of oxidative stress in vitro and in vivo49.
Except for a nearly significant reduction of GSH (p=
0.086) and GSSG (p= 0.088) concentrations in C968-
treated JHH520 cells, we observed no significant effects
on the GSH or GSSG concentrations (Fig. 4d, e). Inter-
estingly, the GSH/GSSG ratio was even increased in
insensitive GLS-low 407 (p= 0.092 for C968) and 233
(p= 0.082 for C968 and p= 0.070 for CB839) cells treated
with GLSi (Fig. 4f). In GBM1 cells, we could not detect
GSSG and thus could not calculate the GSH/GSSG ratio.
This is not uncommon, since reduced GSH makes up on
average 98% of the total GSH content49. Since alterations
in antioxidant levels affect the intracellular clearance of
ROS, we assessed ROS accumulation after treatment with
10 µM C968 or 1 µM CB839 for 24 and 48 h. Except for a
30% increase in ROS accumulation in 233 cells treated
with CB839 for 24 h, CB839 treatment did not induce a
significant increase in intracellular ROS (Fig. 4g). Fur-
thermore, 48 h C968 exposure increased ROS levels in
GLS-high JHH520 (34%) and GLS-low 407 (20%) cells.
The ROS inhibitor N-Acetyl-L-cysteine (NAC) sig-
nificantly reduced and H2O2 significantly increased ROS
accumulation. Consistent with our previous findings,
these results further emphasize the selective mode of
action of GLSi on cells with abundant GLS protein
expression, since especially the observed effects on via-
bility, clonogenicity, cell cycle, and apoptosis were most
pronounced in GLS-high expressing cells.
Glutaminase inhibition with CB839 targets the anabolism
of GSCs by diminishing the influx into the TCA cycle
To see whether metabolic changes cause the phenotypic
effects of GLS inhibition, we used high resolution proton
magnetic resonance spectroscopy (HR 1H NMR) to ana-
lyze intracellular metabolites of JHH520, GBM1, 407, and
233 cells treated with 10 µM C968 or 1 µM CB839. Sur-
prisingly, only CB839 treatment induced the anticipated
changes in GSC metabolites. Blockade of GLS activity by
CB839 led to a significant reduction of the enzyme pro-
duct (Glu), accumulation of the educt (Gln), and
decreased the Glu/Gln ratio in all four cell lines (Fig. 5a,
b). This metabolic phenotype has been validated in several
in vitro and in vivo studies as a reproducible measure of
GLS inhibition14,50,51. Strikingly, upon treatment with
C968 we neither observed reduced product (Glu) con-
centrations nor increased educt (Gln) concentrations,
except for a moderate Glu reduction in 233 cells. Even in
most sensitive JHH520 cells, C968 treatment did not
decrease the Glu/Gln ratio. Since Wang et al. showed
efficient GLS inhibition with 20 µM C968 in hepatocel-
lular carcinoma cells which do not respond to 10 µM
C96820, we additionally measured the GLS activity in GSC
cultures treated with 20 µM C968. However, treatment of
our GSC cultures with 20 µM C968 did not alter the Glu/
Gln ratio and therefore did not inhibit the GLS activity.
Furthermore, CB839, but not C968, reduced intracellular
concentrations of the TCA cycle intermediate succinate
(Suc) and Glu-dependent amino acids aspartate (Asp) and
alanine (Ala) in all four cell lines. We further analyzed
levels of known oncometabolites upon treatment with
C968 and CB839 to see whether GSCs regulate other
metabolic pathways that may compensate for glutami-
nolysis inhibition. In sensitive (JHH520, GBM1) but not
insensitive (407, 233) cells CB839 treatment increased
choline metabolism leading to elevated levels of phos-
phocholine and total choline. In contrast, C968 treatment
had no consistent effect on GSC oncometabolites. Since
we observed reduced Suc, Asp, and Ala levels upon CB839
treatment, we hypothesized that insufficient supply of
TCA cycle intermediates after GLS inhibition disturbs the
anabolism of GSCs causing a decline in the GSC pool. To
test this hypothesis, we tried to rescue the anti-growth
effect of C968 and CB839 by addition of either 4 mM Glu
or 4 mM αKG. The C968 treatment could neither be
rescued by Glu nor αKG (Fig. 5c). In contrast, the anti-
growth effect of CB839 in sensitive JHH520 and
GBM1 cells could be efficiently rescued by both addition
(see figure on previous page)
Fig. 4 CB839 selectively causes cell cycle arrest in GLS-high expressing cultures without inducing apoptosis or oxidative stress. a
Percentage of cells in quiescent (G0/G1), synthesis (S), or mitosis (G2/M) phase after treatment with 10 µM C968, 1 µM CB830, or vehicle (DMSO) for
48 h. The proliferation index (PI= (S+ G2/M)/(G0/G1+ S+ G2/M) x 100%) was calculated to visualize the percentage of proliferative cells. Statistical
significance was tested with two-way ANOVA (n= 3). b The percentages of early apoptotic (EA, AnnexinVpos, 7-AADneg) and late apoptotic (LA,
AnnexinVpos, 7-AADpos) cells in GSC cultures treated for 48 h with 10 µM C968 and 1 µM CB839 were assessed with flow cytometry. c Fold changes in
total apoptotic cells (EA+ LA) of C968- and CB839-treated GSCs compared with cultures treated with DMSO (n= 3 for C968, n= 4 for CB839).
Reduced (GSH) [nmol/mg protein] (d) and oxidized (GSSG) [nmol/mg protein] (e) glutathione was measured in GSCs treated with 10 µM C968, 1 µM
CB830, or vehicle (DMSO) for 48 h. f The ratio of reduced (GSH) and oxidized (GSSG) glutathione in GSCs treated with 10 µM C968, 1 µM CB830, or
vehicle (DMSO) for 48 h (n= 3). g ROS accumulation was measured via DCFDA oxidation over 24 h and 48 h in cells treated with either 10 µM C968,
1 µM CB830, or DMSO. Exposure to 1 mM NAC was used as the negative and exposure to 500 µM H2O2 as the positive control (n= 3). If not specified,
statistical significance was calculated with unpaired t-tests. All data are depicted as mean ± SD (*p < 0.05, **p < 0.01, ***p < 0.001). DMSO
dimethylsulfoxid, GSH glutathione, n.a. not available, NAC N-acetylcysteine, n.s. not significant, ROS reactive oxygen species.
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Fig. 5 CB839 effectively blocks glutaminolysis and reduces the influx into the TCA cycle. a Relative metabolite concentrations of GSC cultures
treated for 48 h with 10 µM C968, 1 µM CB839, or DMSO were assessed with HR 1H NMR spectroscopy of the water-soluble metabolome (n= 3). b
The GLS activity after 48-h treatment with 10 µM C968, 20 µM C968, 1 µM CB839, or DMSO is depicted by the product (Glu) to educt (Gln) ratio of GLS
(n= 3). Cell growth of GSCs treated with 10 µM C968 (c), 1 µM CB839 (d), or DMSO for 48 h either in the presence of medium only, 4 mM Glu, or
4 mM αKG (n= 3). For all assays, statistical significance was calculated with unpaired t-tests. All data are depicted as mean ± SD (*p < 0.05, **p < 0.01,
***p < 0.001). AA amino acids, αKG alpha ketoglutarate, Ala alanine, Asp aspartate, CFU colony forming units, DMSO dimethylsulfoxid, Gln glutamine,
Glu glutamate, Gly glycine, GSH glutathione, Lac lactate, myo-I myo-inositol, n.s. not significant, PC phosphocholine, ppm parts per million, Suc
succinate, TCA tricarboxylic acid, tCho total choline, tCre total creatine.
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of Glu and αKG (Fig. 5d), indicating that CB839 eradicates
GSCs by diminishing TCA-cycle dependent processes
necessary for GSC maintenance and cell cycle progres-
sion. Consistent with our results, previous studies repor-
ted that the maintenance of cancer stem-like cells
depends on a high flux rate through the TCA cycle52,53
and that cell cycle progression in cells is limited by the
availability of biosynthetic precursors from the TCA
cycle54,55. Our 1H NMR data, clearly show that C968 fails
to suppress glutaminolysis, since we neither observed a
reduction in the GLS product Glu, nor any downstream
products of Glu such as Suc, Asp, or Ala upon C968
treatment (Fig. 5a, b). Interestingly, CB839 also induced
metabolic changes in insensitive 407 and 233 cells.
However, the effects were less marked than those
observed in GLS-high expressing JHH520 and
GBM1 cells. We hypothesize that due to the low GLS
baseline expression, 407 and 233 cells are less dependent
on functional GLS.
Discussion
Functional glutaminolysis is crucial for the bioenergetic
and biosynthetic homeostasis especially in proliferative
and invasive cancer cells. Here we show that maintenance
of highly aggressive GSCs markedly depends on intra-
cellular Glu synthesis by GLS and that this dependency
strongly correlates with GLS protein expression. We show
that GLS is expressed in GBM tumors and its level of
expression greatly varies among patients (Fig. 1a). In a
previous study on matching control brain and tumor
samples from GBM patients, it was further shown that
tumors express elevated GLS protein levels26. Moreover,
increased GLS expression has been correlated with higher
grade brain cancers, shortened patient survival, and
temozolomide (TMZ) resistance24. In this manuscript we
show elevated GLS transcription in the invasive front of
GBMs, known to contain highly invasive GSCs35. Previous
publications reported that genetic and pharmacological
inhibition of GLS attenuates stemness properties in
hepatocellular, colorectal, and prostate cancer21,23,43.
Furthermore, our group showed that the prominent route
of anti-GSC therapy using γ-secretase inhibitor MRK003
targets GSC growth, in part by reducing intracellular Glu
as a consequence of GLS inhibition56.
Here we correlate the resistance to GLS inhibition with
reduced protein levels of GLS showing strong phenotypical
consequences in high expressing GSC cultures (SF188,
JHH520, GBM1) but only mild in low expressing GSCs
(233, 407, 268) or non-neoplastic NSCs (Figs. 2, 3). This is
in line with similar observations in triple-negative breast
cancer (TNBC)57. Furthermore, the observed anti-stemness
effect of GLS inhibition has been reported by several studies
highlighting impaired clonogenicity as a major phenotype of
pharmacological and genetic GLS suppression23,43,58.
Recent studies reported that targeted GLS inhibition
further causes cell cycle arrest in prostate and non-small
cell lung cancer19,43. This is consistent with our results
showing cell cycle arrest in G0/G1 and a reduced fraction
of cells in S- and M-phase after treatment with C968
(JHH520, GBM1, 407) and CB839 (JHH520 and GBM1)
(Fig. 4). Again, especially the effectiveness of CB839
treatment correlated with the GLS expression level. Clo-
nogenic GSCs make up just around 10% of our cultures
(max. 10% of plated cells form colonies, Fig. 3), therefore
the observed effects on cell cycle could explain the pro-
found effects on clonogenicity if we assume that GSCs are
especially affected by GLS inhibition.
Off-target effects are a common problem of many
prominent cancer drug candidates in clinical trials59.
Given the increasing attention of GLSi in various cancer
trials, we sought to probe the target specificity of two
leading GLSi compounds with the focus on their func-
tional effects on malignant and nonmalignant stem cells.
We chose C968 given its reproducibly reported ther-
apeutic potential in many cancer studies including our
own19,21,22, and CB839, as one of the leading clinical GLSi
compounds in oncology (trial IDs: NCI-2018-00876, NCI-
2019-01365, NCI-2019-00572). To our knowledge, no
study has explicitly addressed the metabolic consequences
of these compounds in functional assays which score their
therapeutic effects preferentially as a consequence of
effective target suppression. Surprisingly, our pharmaco-
metabolic studies revealed that C968 treatment neither
increased intracellular Gln, nor did it reduce the con-
centrations of Glu, Glu-dependent amino acids (Ala, Asp)
or the TCA cycle intermediate Suc (Fig. 5), all validated
metabolic indicators for successful GLS suppres-
sion51,57,60. This suggests that the phenotypes observed
upon C968 treatment (Figs. 2, 3) cannot be explained by
glutaminolysis suppression. This is supported by our
observations that the effect of C968 treatment could
neither be rescued by addition of Glu nor by replenishing
the TCA cycle with αKG. This strongly suggests that C968
does not affect the enzymatic activity of GLS in GSCs. On
the other hand, since sensitivity towards C968 treatment
positively correlates with elevated GLS protein expression
levels (Figs. 2, 3), the effects cannot solely be explained by
non-specific cytotoxicity and application of metabolic flux
analyses with isotope-labeled Gln are needed to pin-point
the mode of action of this drug candidate.
In contrast, CB839 effectively reduced intracellular Glu
concentration while causing accumulation of Gln (Fig. 5).
Furthermore, CB839 diminished the influx into the TCA
cycle and interfered with GSC anabolism by markedly
reducing the levels of Suc, Ala, and Asp. These observa-
tions are in line with several pharmaco-metabolic studies
showing Gln accumulation and decreased Glu, GSH, and
Asp concentrations upon CB839 treatment14,61. Previous
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studies have reported that cancer stem-like cells depend
on a high flux rate through the TCA cycle52,53, suggesting
that CB839 treatment diminishes the GSC population by
reducing the influx of Glu into the TCA cycle. Indeed,
both addition of Glu and αKG effectively rescued the
phenotype caused by CB839 treatment (Fig. 5). This is in
line with previous research showing that upregulation of
αKG-dependent Gln metabolism and increased GLS
expression promotes the maintenance of cancer stem cells
through various mechanisms26,62–65. Furthermore, Gln
metabolism promotes the maintenance of stemness
through elevating the synthesis of GSH and maintenance
of a balanced redox homeostasis23,66,67. However, we
could neither detect significant accumulation of ROS nor
decreases in the GSH/GSSG ratios in GSCs treated with
CB839 (Fig. 4). Therefore, we conclude that CB839 pre-
dominantly diminishes the GSC pool by disrupting the
influx of Glu into the TCA cycle, thereby limiting the
bioenergetic and biosynthetic supply. Several studies
describe a checkpoint in the late G1 phase of the cell cycle
where the progress into S phase depends on the avail-
ability of precursors for nucleotide biosynthesis54,55.
Therefore, reduced influx into the TCA cycle could
explain the observed cell cycle arrest in G0/G1 phase
upon treatment with CB839.
Taken together, our study clearly shows the potential
of in vitro pharmaco-metabolomics for therapy efficacy
scoring and risk assessment of compounds. Focusing
on GBM and their therapy-resistant stem cell sub-
population, we further highlight the relevance of GLS
as a druggable and promising therapeutic target in our
need to improve the management of GBM therapy
resistance and tumor relapse. Although new platforms
for computational drug target discovery using mole-
cular and cellular data of tumor material enable high
throughput drug design and therapy resistance pre-
diction68, functional assays to biologically confirm
computational biology findings are fundamental for the
translational value of drug development and toxicology
risk assessment. We found that CB839 significantly
outperforms C968 in terms of enzymatic inhibitory
potential and would be the preferred pharmacologic
intervention when aiming at targeting glutaminolysis.
CB839 shows effective GLS inhibition at low µM con-
centrations (1 µM) whereas even high concentrations
of C968 (20 µM) do not affect GLS enzymatic activity.
Our in vitro studies with non-transformed cells high-
light the potential of CB839 as a cancer-specific pre-
cision treatment. Furthermore, our lab is aiming to
improve the cancer cell specificity of CB839 and further
reduce off-target effects by preferentially directing the
delivery of the substance to cancer cells using nano-
technology engineering in a similar approach as
recently described69.
Materials and methods
Cell cultures and primary tissue specimen
Glioma cell line JHH520 was generously provided by G.
Riggins (Baltimore, USA), GBM1 by A. Vescovi (Milan,
Italy), cell lines 23, 233, 268, 349, and 407 by M.S. Carro
(Freiburg, Germany), cell line SF188 by E. Raabe (Balti-
more, USA), and cell line NCH644 (644) by C. Herold-
Mende (Heidelberg, Germany). GSC neurospheres were
cultured in DMEM w/o pyruvate (Gibco, #11965092,
Thermo Fisher Scientific, USA), 30% Ham’s F12 Nutrient
Mix (Gibco, #11765047), 2% B27 supplement (Gibco,
#17504044), 20 ng/ml human bFGF (Peprotech, #AF-100-
18B, USA), 20 ng/ml human EGF (Peprotech, #AF-100-
15), 5 µg/ml Heparin (Sigma, #H0878, Merck KGaA,
Germany), and 1× Anti-Anti (Gibco, #15240096). All cells
were cultured at 37 °C and 5% CO2. Cell lines were reg-
ularity tested for mycoplasma contamination and STR
analyses were performed to guarantee authenticity and
purity. Human fetal cortical tissue was collected in
Cambridge UK under full ethical approval and sent to us
where it was then transferred into cell culture after
mechanic dissociation of cells. The cultures were enriched
for NSCs by propagation in the above described neuro-
sphere medium. Neurospheres were passaged by
mechanical chopping with a McIlwan Tissue Chopper
(Campden Instruments, UK) every week. The study was
conducted in accordance with the Declaration of Helsinki,
and the protocol was approved by the Ethics Committee
of the Medical Faculty of the Heinrich-Heine University
(Study ID #5206). Primary GBM tumor samples were
derived from the operating theater at the department of
neurosurgery (Duesseldorf, Germany) and were snap
frozen in liquid nitrogen until the preparation of lysates
was undertaken. All subjects gave their informed consent
for inclusion before they participated in the study. The
study was conducted in accordance with the Declaration
of Helsinki, and the protocol was approved by the Ethics
Committee of the Medical Faculty of the Heinrich-Heine
University (#2019-484-FmB).
GLS inhibitors
For GLS inhibition we used the small molecule inhibitors
C968 (5-[3-bromo-4-(dimethylamino)phenyl]-2,3,5,6-tet-
rahydro-2,2-dimethyl-benzo[a]phenanthridin-4(1H)-one,
Merck, Germany, #352010) and CB839 (N-[5-[4-[6-[[2-[3-
(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]
butyl]-1,3,4-thiadiazol-2-yl]-2-pyridineacetamide, Cayman
Chemicals, USA, #22038). Stock solutions were prepared in
dimethylsulfoxid (DMSO) and stored at −20 °C.
Western blotting
Cell lysates were electrophoretically separated by SDS
PAGE and transferred onto nitrocellulose membranes as
described previously70. Primary antibodies against CD133
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(1:100, Miltenyi, Germany, #W6B3C1), SOX2 (1:1000,
Cell Signaling Technology, UK, #L1D6A2), GLS (1:1000,
Abcam, UK, #ab93434), ZEB1 (1:2000, Sigma,
#HPA027524), β actin (1:5000, Cell Signaling Technology,
#4970) and α-tubulin (1:10,000, Sigma, #T9026) were
incubated overnight at 4 °C in 5% milk powder in Tris-
buffered saline with 0.1% Tween-20 (TBST). The sec-
ondary antibodies goat-anti-rabbit IRDye800CW
(1:10,000, LI-COR, USA, #926-32211), goat-anti-mouse
IRDye680RD (1:10000, LI-COR #926-68070), and goat
anti-mouse-HRP (1:10,000, Jackson ImmunoResearch,
UK, #111–035–003) were diluted in 5% milk powder in
TBST and incubated for 1 h at room temperature.
Chemiluminescent signals were detected on a film-
based system using chemiluminescent substrates
(Thermo Scientific, #34096). Fluorescence-labeled
antibodies were detected with a LI-COR Odyssey CLx
Imager (LI-COR). Densitometry was performed with
supplied software from LI-COR or ImageJ software71.
For protein analysis of primary tumor samples, tissues
were homogenized in RIPA lysis buffer using a 1 ml
Dounce Homogenizer. Lysates were then incubated for
45 min on ice and centrifuged at 13,000 rpm to yield the
cleared lysate. For the immunoblot in Fig. 1c, we rear-
ranged the individual lanes from lowest to highest GLS
expression to improve visualization of the different
expression patterns. All unprocessed pictures can be
found in supplementary fig. 1. The remaining blots
(Figs. 1, 3c, d) were not cut vertically. For all western
blots, individual genes were tested on the same samples
on the same membrane.
Dual-phase metabolite extraction
Water soluble metabolites were extracted as previously
described70,72,73. In brief, a minimum of 5 × 106 cells per
sample were harvested, washed with PBS, and extracted
with the dual-phase methanol/chloroform/water (1:1:1,
v/v/v) method. The cells were washed twice with 5 ml
ice-cold 0.9 mM NaCl, resuspended in 850 µl ice-cold
ddH2O and transferred into pre-chilled glass tubes.
After addition of 4 ml of ice-cold methanol the tubes
were vortexed vigorously and incubated on ice for
15 min. Then 4 ml of ice-cold chloroform was added,
vortexed, and incubated for 10 min on ice. Finally,
3.15 ml of ice-cold ddH2O was added, vortexed, and
incubated overnight at 4 °C. The samples were cen-
trifuged for 30 min at 4 °C and 4500 rpm. The upper
water-methanol phase was separated and incubated for
10 min with 10 mg Chelex® 100 resin (Sigma, #C7901)
on ice. The samples were filtered through a 70 µm mesh
and the methanol was evaporated for 1 h at 30 °C in a
vacuum concentrator. Finally, the samples were frozen
at −80 °C, lyophilized and stored at −20 °C until spec-
troscopy measurement.
NMR data acquisition and processing
Prior to 1H NMR analysis, the lyophilisates were
resuspended in 20mM phosphate buffer (pH 7.0) con-
taining 10% D2O and 3-(Trimethylsilyl) propionic acid
(TSP; Lancaster Synthesis, USA) as an internal standard
as described previously70.
One-dimensional 1H NMR spectra were acquired with a
Bruker AVANCE III HD 700 spectrometer (Bruker, USA)
equipped with a 5 mm HCN TCI cryo-probe operating at
700MHz (16.4 Tesla). The 1H NMR data were obtained
using excitation sculpting for water suppressing and the
following acquisition parameters: 25 °C sample tempera-
ture, 9800 Hz sweep width, 256 transients with 32K time-
domain data points were accumulated with a repetition
time of 3.2 s as previously described70.
Mestrenova version 8.0.1–10878 (Mestrelab Research S.
L., Spain) software was used to process and analyze the 1H
NMR spectra. Equal concentrations of TSP in each sam-
ple were used as an internal standard for normalization.
The figures show 1H NMR data from a minimum of three
independent experiments presented as mean ± standard
deviation (SD) and statistical significance was calculated
with unpaired Student's t tests. A p value below 0.05 was
considered significant.
Cell viability, apoptosis, and cell cycle assays
Cell viability was assessed as described previously70. In
brief, the cell number was adjusted to 20,000 cells/ml and
triplicates of 100 µl were plated per 96-well. For GLSi
treatment, we plated the cells in neurosphere medium
containing various drug concentrations (1, 5, 10 µM for
C968 and 0.1, 0.5, 1.0 µM for CB839) or vehicle (DMSO).
For the rescue experiments cells were treated with 10 µM
C968, 1 µM CB839, or equal volumes of DMSO and either
4 mM Glu (Sigma, #G1251–100G) or 4 mM αKG (Sigma,
#7589–25G) were added to the different conditions. The
viable cell mass was assessed using the CellTiter-Blue®
Cell Viability Assay (Promega, #G8081) or Thiazolyl Blue
Tetrazolium Bromide (MTT) (Sigma, #2128–1G)
according to the manufacturer’s instructions. For CellTi-
ter-Blue® the fluorescence was measured at 560ex/590em
and for MTT absorbance it was measured at 570 nm
(reference 650 nm) using a Safire 2 multiplate reader
(Tecan, Switzerland). Biological replicates analyzed in Fig.
2: n= 4 for NSC, JHH520, GBM1, 407 (C968), 268
(C968), and SF188 (C968); n= 3 for 233, 407 (CB839),
268 (CB839), and SF188 (CB839).
Apoptosis induction was measured with the “Muse®
Annexin V and Dead Cell Assay Kit” (Merck Millipore,
USA). Therefore, GSCs were cultured in medium con-
taining 10 µM C968, 1 µM CB839, or vehicle (DMSO) for
48 h, stained for Annexin V and 7-AAD according to the
manufacturer’s instructions, and flow cytometry mea-
surements were performed on a Muse® cell analyzer
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(Merck Millipore) as described in the manufacturer’s
instructions.
The cell cycle was analyzed with the “Muse® Cell Cycle
Assay Kit” (Merck Millipore). Cells were treated with
10 µM C968, 1 µM CB839, or vehicle (DMSO) for 48 h,
fixed with ice cold 70% ethanol at −20 °C for at least three
hours and the DNA content was stained according to the
manufacturers’ instructions. Flow cytometry measure-
ments were performed on a Muse® cell analyzer (Merck
Millipore).
Clonogenicity assays
The clonogenicity of GSCs was assessed with colony
forming assays in semi-solid agarose medium as described
previously70. In brief, six-well plates were coated with
1.5 ml of 1% agarose (Gibco, #18300012) in pre-warmed
neurosphere medium. After 1 h incubation at RT, 2 ml of
a single-cell suspension (3000 cells/well) in 0.6% agarose
in neurosphere medium was added. After 1 h incubation
at room temperature, 2 ml neurosphere medium was
added as a top layer. To test the effect of C968 and CB839
on GSC clonogenicity, we either added drugs (10 µM
C968 or 1 µM CB839) or equal volumes of vehicle
(DMSO) to the upper medium layer. Twice a week the top
layer was removed and 2ml fresh medium (with drug or
vehicle) was added. After 3 weeks the top layer was
removed, replaced by 1ml of 1 mg/ml 4-Nitro blue tet-
razolium chloride (NBT) (Sigma, #11383213001) in PBS
and incubated overnight at 37 °C. The stained colonies
were counted using the Clono Counter software74. Figure 3
includes the analysis of three biological replicates (n= 3) for
all cell lines but NSCs. Due to the observed increased
degree of biological variations between the replicates, we
performed the assay with this cell line more often (n= 4
for C968, n= 6 for CB839).
DCFDA ROS assay and GSH/GSSG ratio detection
Accumulation of ROS was measured using 2′,7′-
Dichlorofluorescin diacetate (DCFDA) (Sigma, #D6883).
Briefly, JHH520, GBM1, 407, and 233 cells were washed
with PBS once and resuspended in PBS containing 50 µM
DCFDA. After incubation of 30 min at 37 °C, cells were
again washed with PBS, resuspended in neurosphere
medium, and 3 × 105 cells per condition were transferred
into flasks containing either drugs (10 µM C968 or 10 µM
CB839) or equal volumes of vehicle (DMSO). The cells
were incubated for 24 or 48 h at 37 °C under standard cell
culture conditions. As a negative control, cells were
incubated with 3 mM of the ROS inhibitor NAC for 24 h,
as a positive control, cells were incubated with 500 µM
H2O2 for 30 min. After 24 or 48 h the cells were washed
once with PBS and resuspended in 700 µl PBS. For every
condition, 200 µl triplicates of each condition were
transferred into 96-well microplates. Fluorescence was
measured at 493em/515ex on a Safire 2 multiplate reader
(Tecan).
For the quantification of the total reduced GSH and
GSSG content we used the “GSH/GSSG Ratio Detection
Assay Kit” (abcam, #ab138881) according to the manu-
facturer’s instructions. In brief, GSC cultures were treated
with either 10 µM C968 or 1 µM CB839 for 48 h. Subse-
quently, the total protein content was measured using the
“DC™ Protein Assay Kit II” (BioRad, #5000112) according
to the manufacturer’s instructions. The cells were lysed in
0.5% NP40 in PBS, centrifuged for 15min at 13,000 rpm
and 4 °C, and the supernatant was used in a deproteini-
zation reaction. Therefore, proteins were precipitated
with 4M phosphochloric acid diluted to a final con-
centration of 1M within the cell lysate. After 2 min of
centrifugation at 13,000 rpm at 4 °C, the cleared super-
natant was then neutralized to pH 4–6 by addition of 2M
KOH. This deproteinized lysate was then analyzed with
the above mentioned GSH/GSSG Ratio Detection Assay
Kit. The detected reduced and oxidized GSH (nmol) was
then normalized to the total protein content (mg) of the
respective samples.
RNA sequencing data from IVY Glioblastoma Project
As described previously70 RNA sequencing data were
generated from anatomic structures isolated by laser
microdissection. Five tumor structures (leading edge n=
19, infiltrating tumor n= 25, cellular tumor n= 112,
perinecrotic zone n= 27, and pseudopalisading cells
around necrosis n= 41) were identified by H&E staining
and compared with hyperplastic blood vessels (n= 23)
and the microvascular proliferative region (n= 29). A
total of 122 RNA samples were generated from 10 tumors
and used for sequencing. The data were retrieved in
March 2018. Website: ©2015 Allen Institute for Brain
Science. Ivy Glioblastoma Atlas Project [Internet]. Avail-
able from: glioblastoma.alleninstitute.org.
Statistical analyses
All statistics were performed with GraphPad Prism
Software Version 8.0.2 (GraphPad Software Inc., USA).
All results are presented as mean ± SD from a minimum
of at least three independent biological replicates. To
calculate statistical significance in an experiment with two
conditions (treated vs. untreated) we performed two-
tailed t-tests. When more than two conditions were
compared with each other (mRNA expression data) we
performed one-way ANOVA analyses and Bonferroni’s
tests for multiple comparisons. If applicable, normal dis-
tribution was confirmed with the Shapiro–Wilk method.
For all experiments, significance was defined as a p value
below 0.05.
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